Cite
HARVARD Citation
Pal, S. et al. (2022). Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 400 (10358), pp. 1103-1116. [Online].